

**Table 2. Characteristics of and seroconversion data from longitudinal and cohort studies of HIV transmission, by condom usage category, according to direction of transmission**

Entry date	Study*	Study site	Predominant mode of infection†	Follow-up (interval)‡	Condom usage§		
					Never	Some	Always
<b>Male-to-female transmission</b>							
1978	Peterman TA	U.S.	Transfusion	34.7	10/51	0/4	na
1984	van der Ende ME	Netherlands	Hemophilic	36 (3)	0/8	0/3	0/2
1985	Laurian Y	France	Hemophilic	24 (6)	3/17	na	0/14
1987	Kamenga M	Zaire	Heterosexual	15.4 (6)	na	1/10	1/50
1987	Allen S	Rwanda	Heterosexual	25.3 (3)	4/10	2/16	0/4
1987	Saracco A	Italy	Intravenous drug use	18.5 (6)	8/79	8/55	3/171
1987	European Study Group	Europe	Intravenous drug use	24.5 (6)	na	8/74	0/83
1988	Hira SK	Zambia	Heterosexual	18 (3)	na	5/49	0/30
Total seroconversions					25/165	24/211	4/354
Seroconversion rate					15.2%	11.4%	1.1%
<b>Female-to-male transmission</b>							
1978	Peterman TA	U.S.	Transfusion	31.6	2/23	0/2	na
1987	Kamenga M	Zaire	Heterosexual	15.4 (6)	na	1/1	3/55
1987	Allen S	Rwanda	Heterosexual	27.6 (3)	2/3	0/15	0/5
1987	European Study Group	Europe	Intravenous drug use	24.5 (6)	na	4/47	0/41
Total seroconversions					4/26	5/65	3/101
Seroconversion rate					15.4%	7.7%	3.0%
<b>Transmission direction not stated</b>							
1983	Fischl MA	U.S.	Mixed	24** (6)	12/14	1/10	na
1987	O'Brien TR	U.S.	Transfusion	30 (6)	0/2	0/4	na
1988	Siddiqui NS	U.S.	Intravenous drug use	12.5 (3.5)	0/9	0/6	0/7
1988	Deschamps M	Haiti	Heterosexual	25.7†† (3)	13/90	6/45	1/42
Total seroconversions					25/115	7/65	1/49
Seroconversion rate					21.7%	10.8%	2.0%

\*First author. †In index case. ‡Mean duration of follow-up (in months), with follow-up interval in parenthesis. §Cumulative frequencies of HIV seroconversion, by condom usage category. \*\*Median. ††24.7 never, 28.9 always. Note: na=not applicable. Sources: M Deschamps, 1996 (reference 1); for all others, reference 21.